Section Arrow
Quote
XTLB.NASDAQ
- XTL Biopharmaceuticals Ltd
Quotes are at least 15-min delayed:2025/05/14 04:18 EDT
Last
 1.251
-0.049 (-3.77%)
Day High 
1.38 
Prev. Close
1.3 
1-M High
1.74 
Volume 
2.16K 
Bid
1.17
Ask
1.38
Day Low
1.251 
Open
1.35 
1-M Low
0.99 
Market Cap 
11.46M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.38 
20-SMA 1.31 
50-SMA 1.26 
52-W High 3.15 
52-W Low 0.9208 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.30/-0.71
Enterprise Value
11.46M
Balance Sheet
Book Value Per Share
0.62
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
451.00K
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
PLRZPolyrizon Ltd0.0285-0.3215-91.86%-- 
CNSPCNS Pharmaceuticals Inc.1.36+0.15+12.40%0PE
NCNANuCana plc0.0329-0.0071-17.75%-- 
HCWBHCW Biologics Inc10.05+4.84+92.90%-- 
XLOXilio Therapeutics1.15+0.419+57.32%-- 
Quotes are at least 15-min delayed：2025/05/14 04:18 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.